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ABSTRACT
Introduction: Diuretic responsiveness in
patients with chronic heart failure (CHF) is
better assessed by urine production per unit
diuretic dose than by the absolute urine output
or diuretic dose. Diuretic resistance arises over
time when the plateau rate of sodium and water
excretion is reached prior to optimal fluid
elimination and may be overcome when
hypertonic saline solution (HSS) is added to
high doses of furosemide.
Methods: Forty-two consecutively hospitalized
patients with refractory CHFwere randomized in
a 1:1:1 ratio to furosemide doses (125 mg,
250 mg, 500 mg) so that all patients received
intravenous furosemide diluted in 150 ml of
normal saline (0.9%) in the first step (0–24 h)
and the same furosemide dose diluted in 150 ml
of HSS (1.4%) in the next step (24–48 h) as to
obtain 3 groups as follows: Fourteen patients
receiving 125 mg (group 1), fourteen patients
receiving 250 mg (group 2), and fourteen
patients receiving 500 mg (group 3) of
furosemide. Urine samples of all patients were
collected at 30, 60, and 90 min, and 3, 4, 5, 6, 8,
and 24 h after infusion. Diuresis, sodium
excretion, osmolality, and furosemide
Electronic supplementary material The online
version of this article (doi:10.1007/s12325-015-0254-9)
contains supplementary material, which is available to
authorized users.
S. Paterna  F. Balistreri  D. Torres  U. Lupo 
F. Cuttitta  G. Parrinello (&)
Dipartimento Biomedico di Medicina Interna e
Specialistica (DIBIMIS), AOUP ‘‘Paolo Giaccone’’
Universita` degli Studi di Palermo, Palermo, Italy
e-mail: gaspare.parrinello@unipa.it
F. Di Gaudio  M. Greco  S. Indelicato
Dipartimento Biopatologia e Biotecnologie Mediche
e Forensi (DiBiMEF), AOUP ‘‘Paolo Giaccone’’
Universita` degli Studi di Palermo, Palermo, Italy
V. La Rocca
Dipartimento Energia, Ingegneria dell’Informazione
e Modelli Matematici (DEIM), Universita` degli Studi
di Palermo, Palermo, Italy
G. Rizzo
UO Medicina D’Urgenza e Pronto Soccorso AOUP
‘‘Paolo Giaccone’’ Universita` degli Studi di Palermo,
Palermo, Italy
P. di Pasquale
UO di Cardiologia ‘‘Paolo Borsellino’’, Ospedale GF
Ingrassia Palermo, Palermo, Italy
J. Butler
Cardiology Division, Stony Brook University,
Stony Brook, NY, USA
Adv Ther (2015) 32:971–982
DOI 10.1007/s12325-015-0254-9
concentration were evaluated for each urine
sample.
Results: After randomization, 40 patients
completed the study. Two patients, one in
group 2 and one in group 3 dropped out. Patients
in group 1 (125mg furosemide) had amean age of
77± 17 years, 43% were male, 6 (43%) had heart
failure with a preserved ejection fraction (HFpEF),
and 64% were in New York Heart Association
(NYHA) class IV; the mean age of patients in
group 2 (250 mg furosemide) was 80± 8.1 years,
15%weremale, 5 (38%) hadHFpEF, and 84%were
in NYHA class IV; and the mean age of patients in
group 3 (500 mg furosemide) was 73± 12 years,
54%weremale, 6 (46%) hadHFpEF, and 69%were
in NYHA class IV. HSS added to furosemide
increased total urine output, sodium excretion,
urinary osmolality, and furosemide urine delivery
in all patients and at all time points. The
percentage increase was 18,14, and 14% for urine
output; 29, 24, and16%for total sodiumexcretion;
45, 34, and 20% for urinary osmolarity; and 27, 36,
and32%for total furosemideexcretion ingroups1,
2, and 3, respectively. These findings were
translated in an improvement in the furosemide
dose–response curves in these patients.
Conclusion: These results may serve as new
pathophysiological basis for HSS use in the
treatment of refractory CHF.
Keywords: Dose–response curves; Furosemide;
Heart failure; Hypertonic saline; Refractory
chronic heart failure
INTRODUCTION
Heart failure (HF) is characterized by progressive
fluid accumulation and a gradually decreased
response to diuretic therapy [1]. Although the
overall impact of diuretic therapyonHFmortality
remains unclear, diuretics remain a mainstay of
HF therapy [2, 3]. However, chronic treatment
with diureticsmay result in a phenomenon called
‘‘chronic braking’’ which limits the diuretic
response and deteriorates the clinical status.
When the sodium and water excretion rate
plateaus are achieved before adequate fluid
elimination, a condition known as diuretic
resistance occurs [4]. Pharmacokinetic and
pharmacodynamic alterations are thought to be
responsible for diuretic resistance in patientswith
HF [5]. As a matter of fact, the chronic use of loop
diuretics leads to a functional adaptation of the
distal tubule that alters its ability for reabsorption
and results in diuretic resistance [6]. Sodium
reabsorption in the distal tubule increases
significantly when loop diuretics augment
sodium delivery to this segment.
Brater et al. [7] described the response to
intravenous (IV) furosemide administration
using a fit sigmoid-shaped curve in patients
with HF and in healthy controls evidencing that
in HF, the curve shifts down and to the right
indicating reduced furosemide and sodium
excretion into urine. Moreover, several studies
in patients with chronic HF (CHF) have
reported that IV infusion of hypertonic saline
solution (HSS) plus high-dose furosemide is
more effective than furosemide alone [8–12],
resulting in increased urine output. These
findings have allowed for greater weight loss, a
shorter length of hospitalization [13–16], a
greater reduction in neurohormonal activation
[17], and a significant improvement in renal
function [18–21].
To validate the promising effects of HSS
administration, the primary endpoint of the
present study was to investigate the behavior on
the dose–response curve after IV administration
of high doses of furosemide diluted in HSS in
comparison with the same dose of furosemide
diluted in normal saline in patients hospitalized
with refractory CHF.
972 Adv Ther (2015) 32:971–982
METHODS
Patients were suitable for recruitment if they
had presented with acute decompensated HF in
the previous 24 h; diagnosis was made on the
basis of the manifestation of at least one
symptom (dyspnea, orthopnea, or edema) and
one sign (pulmonary rales, lower limb edema,
ascites, or lung vascular congestion on chest
radiography) of HF according to European
Society of Cardiology Criteria [22]. Additional
inclusion criteria were a history of CHF treated
with oral loop diuretics, at a dose of between
125 mg and 500 mg daily of furosemide, for at
least 1 month before hospitalization. There
were no pre-specified inclusion criteria
regarding left ventricular ejection fraction
(LVEF). Patients with 90 mm Hg or less of
systolic blood pressure (BP) or with a serum
creatinine level[2.5 mg/dL (265.2 lmol/L)
were excluded. In addition, patients who
needed vasodilators or inotropic agents via IV
(other than digoxin) or non-steroidal
anti-inflammatory drugs were also excluded.
Protocol was carried out following the
principles of the Helsinki Declaration of 1964,
and subsequent revisions, and in accordance
with national legislations. The hospital’s
Internal Review Board and its Ethics
Committee approved the protocol and all
patients signed a written informed consent
(Fig. 1).
The study involved 42 consecutively
hospitalized patients with refractory CHF
fulfilling all of the eligibility criteria. Patients
were randomly assigned in a 1:1:1 ratio to
furosemide doses (125 mg, 250 mg, 500 mg) so
that all patients received both IV infusions
Fig. 1 Flow chart of the study protocol. Iv intravenous
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over 20 min every 24 h, the first of which
contained furosemide diluted in 150 mL of
normal saline (0.9%) and the last the same
furosemide dose diluted in 150 mL of HSS
(1.4%). Randomization was performed with
the use of a preliminary computer algorithm,
and a complete clinical examination and
laboratory measurements were carried out
before it.
An independent team of nurses prepared the
solutions and had an independent physician
follow the process. A complete physical
examination, including body weight (BW), BP,
and heart rate (HR), was performed in all
selected patients after randomization. Serum
Na, K, Cl, bicarbonate, albumin, uric acid,
creatinine, blood urea nitrogen (BUN) and
glucose were determined through venous
blood samples before treatment. Just after IV
bolus of furosemide, urine samples were
collected and measured using an urinometer,
according to the protocol described by Brater
et al. [7], at 30, 60, and 90 min, and at 3, 4, 5, 6,
8, and at 24 h (T1–T9) after normal saline and
HSS. This was given in association with fluid
intake restriction (1000 mL/day) and a dietary
sodium intake of 2.8 g/day (120 mmol/day).
Urine samples were consecutively numbered
and signed by physicians blinded to the study
protocol, and immediately frozen at -20 C.
Samples were subsequently delivered to the
Regional Quality Control Laboratory (RQCL)
for the quantification of urinary furosemide,
natriuresis, and osmolality and analyzed by an
external blinded team of physicians. Urinary
excretion of furosemide was assayed with
HPLC–MS/MS (High-Performance Liquid
Chromatography–tandem mass spectrometry)
method [13]. Urine furosemide excretion data
was processed by an external computer
scientist, blinded to the study protocol, to
obtain dose–response curves.
Echocardiographic Analysis
Echocardiograms using a GE VividTM 7
Dimension (GE Healthcare) ultrasonography
were detected at entry and 48 h later at the
end of the protocol. Standard parasternal and
apical views images were acquired with a
phased-array transducer in the left lateral
decubitus position. The average of three
consecutive cycles was calculated to determine
all echocardiographic measurements. LV
volumes, LVEF, mitral regurgitation, and left
atrial maximum volume were assessed
according to the American Society of
Echocardiography criteria [23].
Furosemide Determination
Standard solutions of furosemide and
hydrochlorothiazide (HCT; purities C98%
and C99%, respectively) were obtained from
Sigma-Aldrich (St. Louis, MO, USA). Methanol
(purity LC–MS) was obtained from JT Baker
(Avantor Performance Materials, Inc., Center
Valley, PA, USA). Formic acid (purity
approximately 98%) was obtained from
Sigma-Aldrich. The water used, HPLC-grade,
was obtained from distilled water for
purification, via the purification system
Barnstead Nanopure Diamond (Thermo Fisher
Scientific, Palo Alto, CA, USA). Stock solutions
of furosemide and HCT (used as internal
standard) were obtained by dissolving 15.0 mg
of standard solids, accurately weighed, in
100 mL of methanol, obtaining solutions of
150 mg L-1 (150 ppm) concentration, which
were stored at -20 C. Working solutions used
for the analysis in LC–MS/MS or for the creation
of urine samples fortified were obtained starting
from stock solutions by dilution with water or
methanol, using a dilution factor less than 10 in
each step of dilution.
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HPLC–MS/MS Analysis [24]
LC–MS/MS analyses were performed using an
HPLC Accela 1000 (Thermo Fisher Scientific)
equipped with a refrigerated autosampler,
degasser, and thermostatic chamber for the
column chromatographic, interfaced to a
tandem-mass high-resolution spectrometer
Q-Exactive (Thermo Fisher Scientific) coupled
with atmospheric pressure heated source, H-ESI
II. Chromatographic separation was obtained
using a Thermo HyperSil Gold C18 PFP column
(50 mm 9 2.1 mm i.d., 1.9 lm particle size),
thermostated at 25 C. The chromatographic
run was performed using the method on
gradient concentration of two eluents: A
(water ? 0.1% formic acid) and B
(methanol ? 0.1% formic acid). 100 lL of
centrifuge urine, placed in a 1-mL volumetric
flask, was added with 10 lL of HCT solution
(concentration 50 mg L-1) and was brought to
the final volume with HPLC-water. 5 lL of the
resulting solutions were directly injected into
the chromatographic system. Quantification of
the samples was carried out using calibration
curves of furosemide in matrix, according to the
internal standard method, in the range between
0.025 and 15 mg L-1. The fortified urine
samples used for the calibration curves were
obtained by adding to 100 lL of centrifuged
blank urine, appropriate volumes of working
solution of furosemide and a fixed volume of
10 lL of HCT (50 mg L-1) and brought to the
final volume of 1 mL, with HPLC-grade water.
Chromatograms obtained were processed using
the quantification tool Quan Browser Xcalibur
(Thermo Electron Corporation). Calibration
curves were obtained by plotting the
relationship between the values
chromatographic areas—obtained by
extrapolating the track in full scan signal
relative to the ion of mass number/charge
number (m/z) 328.9993 (furosemide) and m/z
295.9572 (HCT) (with a tolerance of 5 ppm on
the reading value of m/z)—versus the
concentration of furosemide. At the beginning
and end of each run, two calibration curves
were inserted and the straight curves obtained
reported R2 values P[0.9978.
Data Analysis
Computer fitting to a sigmoid-shaped curve of
furosemide excretion rate and response
‘‘dose–response curves’’ relationship was
examined using the following formula:
Y ¼ a d
1þ Xc
 
b
þ d
where Y (response) is the urinary sodium
excretion rate, X is the furosemide excretion
rate, a is the lower asymptote (i.e., response
when dose = 0), b is the ‘‘slope factor’’ that
determines inclination of the curve; c is the
dose representing half-maximal response
(d - a)/2, and d shows the upper asymptote
(i.e., response when dose =?). Individual data
were fit and compared using the ALLFIT
computer program [25]. For each curve, the
software assigns a P value, which represents an
index of representativeness of the curve
compared to experimental data: good
(P[0.05), poor (P\0.05), and bad (P\0.01),
as indication of the quality of the curve fit.
RESULTS
After randomization, the three groups of
patients who received one of the IV diuretic
dosages were: fourteen patients who received
125 mg of furosemide (group 1), thirteen
patients who received 250 mg of furosemide
(group 2), and thirteen patients received
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500 mg of furosemide (group 3). One patient in
group 2 and one patient in group 3 dropped out
because they did not tolerate the bladder
catheterization and were therefore not
analyzed. A comparison of the baseline
features of the cohorts of randomized patients
is shown in Table 1. The mean age of the
patients in group 1 (125 mg) was 77 ± 17 years,
43% were male, 6 (43%) had heart failure with a
preserved ejection fraction (HFpEF), and 64%
Table 1 Baseline characteristics of the study participants, according to treatment group
Characteristic Group 1 (125 mg)
(N5 14)
Group 2 (250 mg)
(N5 13)
Group 3 (500 mg)
(N5 13)
Age (years) 77 ± 17 80 ± 8.1 73 ± 12
Sex, male 6 (43) 2 (15) 7 (54)
NYHA class IV 9 (64) 11 (84) 9 (69)
Preexisting condition(s)
Coronary artery disease 5 (35) 3 (23) 5 (38)
Hypertension 10 (71) 12 (92) 9 (69)
Atrial ﬁbrillation 8 (57) 4 (31) 6 (46)
Diabetes 5 (35) 3 (23) 5 (38)
HFpEF 6 (43) 5 (38) 6 (46)
Peripheral edema (4 ?/4 ?) 6 (43) 7 (53) 6 (60)
Medication
ACE inhibitor or ARB 6 (43) 6 (46) 6 (46)
Beta-blocker 6 (43) 6 (46) 6 (46)
Aldosterone antagonist 2 (14) 1 (7) 2 (15)
Digitalis 4 (28) 3 (23) 4 (31)
Furosemide 14 (100) 13 (100) 13 (100)
Clinical and laboratory evaluation(s)
Serum sodium (mEq/L) 141.1 ± 2.8 138.5 ± 3.4 140.3 ± 3.8
Creatinine (mg/dL) 1.1 ± 0.4 1.2 ± 0.5 1.2 ± 0.4
BUN (mg/dL) 64 ± 26 64 ± 33 69 ± 27
GFR–MDRD (mL/mim) 65 ± 21 60 ± 36 58 ± 27
Systolic blood pressure (mm Hg) 128 ± 14 128 ± 19 128 ± 15
Heart rate (beats/min) 76 ± 13 82 ± 16 81 ± 12
Ejection fraction (%) 44 ± 13 42 ± 14 45 ± 10
Values are presented as n (%) or mean ± standard deviation
ACE angiotensin converting enzyme, ARB angiotensin receptor blockers, BUN blood urea nitrogen, GFR glomerular
ﬁltration rate, HFpEF heart failure with preserved ejection fraction, MDRD modiﬁcation of diet in renal disease, NYHA
New York Heart Association
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were in New York Heart Association (NYHA)
class IV; the mean age of patients in group 2
(250 mg) was 80 ± 8.1 years, 15% were male, 5
(38%) had HFpEF, and 84% were in NYHA class
IV; the mean age of patients in group 3
(500 mg) was 73 ± 12 years, 54% were male, 6
(46%) had HFpEF, and 69% were in NYHA class
IV. There were no substantial differences
between the groups, neither in CHF etiology
nor in the different types of medical therapy. All
patients were receiving treatment with
furosemide orally, overall 45% had severe
lower limb edema, and 43% had a reduced
LVEF. No significant differences in serum
sodium, creatinine, blood urea nitrogen
(BUN), systolic blood pressure (BP), and heart
rate (HR) were found between the groups
(Table 2). Total furosemide excretion, urinary
osmolarity, urinary sodium, and 24-h diuresis in
the study population after furosemide plus HSS
administration in comparison with furosemide
plus normal saline baseline are presented in
Fig. 2. The addition of HSS to furosemide dose
improved total diuresis, urine osmolarity,
furosemide, and sodium excretion in all
groups. There was an increase in the excretion
of furosemide of between 27% and 36% and in
the total sodium excretion of between 16% and
29% when HSS was added. An increase in 24-h
urine output of between 14% and 18%
compared to baseline was also observed.
Similar behavior was observed for total urinary
osmolality (Table 3). The link between
furosemide release and natriuretic response is
shown in Fig. 3. Each point represents the
median of one urine collection period and the
curve encompassed the time course of the entire
study (24 h). In approximately 85% of curves,
the software assigned a good P value (P[0.05)
indicating the quality of the curve. In all
groups, the median of furosemide plus HSS
shows a dose–response curve up and to the left
while the median dose response curve obtained
with furosemide plus normal saline is down and
on the right.
DISCUSSION
The amount of drug reaching the renal tubule is
the most important determinant of the
response to a diuretic [26]. The drug can be
quantified by the ratio of sodium excretion
Table 2 Clinical parameters and renal metrics at different furosemide dosages in the study populations
Parameters Group 1 (125 mg) (N5 14) Group 2 (250 mg) (N5 13) Group 3 (500 mg) (N5 13)
Normal
saline
Hypertonic
saline
P Normal
saline
Hypertonic
saline
P Normal
saline
Hypertonic
saline
P
SBP (mm Hg) 128 ± 14 117 ± 14 0.04 128 ± 19 119 ± 16 0.2 128 ± 15 118 ± 10 0.05
HR (beats/min) 76 ± 13 72 ± 9 0.3 82 ± 16 73 ± 13 0.1 81 ± 12 68 ± 7 0.003
Serum sodium
(mEq/L)
141 ± 3 140 ± 3 0.4 138 ± 3 140 ± 2 0.05 140 ± 3 141 ± 2 0.32
BUN (mg/dL) 64 ± 26 60 ± 23 0.6 64 ± 32 79 ± 29 0.2 69 ± 35 87 ± 33 0.19
Creatinine
(mg/dL)
1.1 ± 0.4 1.0 ± 0.4 0.5 1.2 ± 0.5 1.2 ± 0.3 1 1.2 ± 0.4 1.4 ± 0.4 0.21
Values are presented as mean ± standard deviation. Normal saline (0.9%) and hypertonic Saline (1.4%). BUN blood urea
nitrogen, HR heart rate SBP systolic blood pressure
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relative to urinary diuretic concentration [27].
Glomerular filtration rates are relatively normal
in most patients with CHF but their renal blood
flow is reduced [28]. Since furosemide gains
access to its intraluminal site of action by active
secretion at the proximal tubule, a decreased
blood flow could limit delivery to the secretory
site. Consequently, patients with CHF may not
respond because of reduced delivery of diuretic
to the site of action. The present study suggests
that furosemide tubular delivery increases over
time in all groups but a higher furosemide
concentration is observed when HSS is added.
The relationship between excretion of sodium
and urine furosemide delivery was represented
as a curve encompassing the time course of the
entire study, fitted as a sigmoid function. To
explain these data, we assumed that the effect of
the infusion of HSS has realized a dual action
that would justify the observed variation of the
excretion pattern of sodium and furosemide,
and, therefore, the shift of the dose–response
curve at the top and to the left, with a
closer-to-physiology pattern. The shift at the
top of the curve intuitively reflects the increased
urinary sodium observed in the whole study
(A) (B)
(C) (D)
Fig. 2 Changes in a furosemide excretion, b 24-h diuresis, c urinary sodium, and d urinary osmolality in all patients treated
at different furosemide dosages (mean ± SD). FUR furosemide, HSS hypertonic saline solution
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population after HSS infusion. Moreover, the
observation that urinary osmolarity, urinary
sodium, and 24-h diuresis were higher at all
dosages of diuretic administration when HSS
was added is the consequence of major
furosemide and sodium excretion. Such
consequences were probably due to the
favorable diuretic effects of HSS that modified
pharmacokinetics and pharmacodynamics of
furosemide. In fact, due to its osmotic effect,
HSS causes a fast and instantaneous
mobilization of fluids from the third space to
the vascular compartment, without a significant
simultaneous rising of serum sodium. HSS
exerts its positive effects in the kidney acting
as a sort of ‘‘bait’’ for the action of the diuretic
by facilitating its action with a twofold effect
[29, 30]. Intuitively, these results are reliable
with an increase in effective kidney blood
volume that leads to an explanation for the
quantitative and qualitative variations of urine.
Another explanation may consist in the
functional attitude of the kidney that changes
in response to a load of sodium and water. Deep
nephrons, due to their well-developed loops of
Henle, are more efficient in the reabsorption of
water and sodium (salt-saving nephrons) while
superficial nephrons due to their short
developed loops of Henle are more efficient in
the excretion of water and sodium (salt-losing
nephrons) [31]. During increased loads of water
and sodium occurring after administration of
HSS, there is a change in the auto regulation of
renal plasma flow, more marked in the cortex
rather than in the renal medulla, and, as a
consequence, blood flow is increased and the
filtration rate in the superficial nephrons
(salt-losing nephrons) is also increased [31].
The present investigation shows that the
beneficial effects of HSS evidenced in previous
studies [8–12, 15, 16] are supported by the fact that
HSS administered in conjunction with furosemideT
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improves diuretic and sodium excretion rate, and
subsequently shifts the furosemide dose–response
curves up and to the left. These data suggest that
this approach is effective, andmaybe adopted into
routine care and should serve as a new
pathophysiological basis for the management of
decompensated refractory CHF. Moreover, these
data, if confirmed, add new insights in
understanding mechanisms of diuretic
administration in patients with CHF.
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